Decreased Efficiency of Potassium-Titanyl-Phosphate Laser Photoselective Vaporization Prostatectomy with Long-Term 5 alpha-Reductase Inhibition Therapy: Is it True?

Urology

Volumn 70, Issue 5, 2007, Pages 927-930

  Araki, Motoo ^a   Lam, Po N ^a   Culkin, Daniel J ^a   Wong, Carson ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DUTASTERIDE; FINASTERIDE; HEMOGLOBIN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLADDER CONTRACTION; BLADDER NECK CONTRACTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMATURIA; HUMAN; LASER; LASER SURGERY; LONG TERM CARE; MAJOR CLINICAL STUDY; PHOTOSENSITIVE VAPORIZATION PROSTATECTOMY; POSTOPERATIVE PERIOD; POSTVOID RESIDUAL URINE VOLUME; POTASSIUM TITANYL PHOSPHATE LASER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATECTOMY; RETROGRADE EJACULATION; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URETHRA STRICTURE; URETHRAL MEATUS STENOSIS; URINARY TRACT INFECTION; URINE FLOW RATE;

AGED; AZASTEROIDS; CHOLESTENONE 5 ALPHA-REDUCTASE; COMBINED MODALITY THERAPY; FINASTERIDE; HUMANS; LASERS, SOLID-STATE; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; TIME FACTORS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 36549039603     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.06.1152     Document Type: Article

References (21)

1. Lepor H., and Rigaud G. The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 143 (1990) 533-537
2. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
3. Bachmann A., Ruszat R., Wyler S., et al. Photoselective vaporization of the prostate: the basel experience after 108 procedures. Eur Urol 47 (2005) 798-804
4. Bachmann A., Schurch L., Ruszat R., et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol 48 (2005) 965-971 discussion 972
5. Malek R.S., Kuntzman R.S., and Barrett D.M. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 174 (2005) 1344-1348
6. Te A.E., Malloy T.R., Stein B.S., et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 172 (2004) 1404-1408
7. Kuntzman R.S., Malek R.S., Barrett D.M., et al. Potassium-titanyl-phosphate laser vaporization of the prostate: a comparative functional and pathologic study in canines. Urology 48 (1996) 575-583
8. Lekas E., Bergh A., and Damber J.E. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int 85 (2000) 962-965
9. Pareek G., Shevchuk M., Armenakas N.A., et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169 (2003) 20-23
10. Rittmaster R.S., Norman R.W., Thomas L.N., et al. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 81 (1996) 814-819
11. Kearney M.C., Bingham J.B., Bergland R., et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 167 (2002) 2489-2491
12. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
13. Puchner P.J., and Miller M.I. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 154 (1995) 1779-1782
14. Foley S.J., Soloman L.Z., Wedderburn A.W., et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 163 (2000) 496-498
15. Donohue J.F., Hayne D., Karnik U., et al. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 96 (2005) 1319-1322
16. Hochberg D.A., Basillote J.B., Armenakas N.A., et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 167 (2002) 1731-1733
17. Steers W.D. 5alpha-reductase activity in the prostate. Urology 58 (2001) 17-24 discussion 24
18. Tinmouth W.W., Habib E., Kim S.C., et al. Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection?. J Endourol 19 (2005) 550-554
19. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
20. Lloyd S.N., Collins G.N., McKelvie G.B., et al. Predicted and actual change in serum PSA following prostatectomy for BPH. Urology 43 (1994) 472-479
21. Te A.E., Malloy T.R., Stein B.S., et al. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicenter study at 3 years. BJU Int 97 (2006) 1229-1233